Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-05-05Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects [Phase 1]
Phase 1 pharmacokinetics and pharmacodynamics study of saxagliptin in healthy subjects. The trial was sponsored by AstraZeneca and is comple…
-
CLINICAL_TRIALS trial_result · 2015-05-05Clinical Trial Update: The Effect of Whey Protein Consumed as a Pre-meal on Postprandial Lipemia in Healthy and Subjects With Type 2 Diabetes [NA]
Completed clinical trial evaluating whether pre-meal whey protein affects postprandial lipemia in healthy individuals and in people with Typ…
-
CLINICAL_TRIALS research · 2015-05-05Clinical Trial Update: Vascular Reactivity in Kidney Disease Patients [NA]
A completed clinical trial update on vascular reactivity in patients with chronic kidney disease and diabetes mellitus type 1 or type 2.
-
CLINICAL_TRIALS trial_result · 2015-05-04Clinical Trial Update: A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) [Phase 3]
Phase 3 trial evaluating adding sitagliptin to stable sulfonylurea therapy (with/without metformin) in adults with type 2 diabetes; complete…
-
CLINICAL_TRIALS trial_result · 2015-05-04Clinical Trial Update: Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations [NA]
This clinical trial update reports the completion of a study evaluating lifestyle modification to reduce post-meal blood glucose elevations …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-05-01Clinical Trial Update: Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes [Phase 2]
A Phase 2 safety and tolerability trial of MBX-2044 in patients with Type 2 Diabetes Mellitus has completed, reporting safety and tolerabili…
-
CLINICAL_TRIALS trial_result · 2015-05-01Clinical Trial Update: Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin [Phase 2, Phase 3]
Completed Phase 2/Phase 3 trial evaluating safety and efficacy of Metaglidasen in adults with Type 2 diabetes mellitus suboptimally controll…
-
CLINICAL_TRIALS research · 2015-04-30Clinical Trial Update: Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior [Phase 1]
Phase 1 clinical trial update investigating EEG operant conditioning as a way to improve trait self-control and promote healthier behaviors …
-
CLINICAL_TRIALS trial_result · 2015-04-30Clinical Trial Update: Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics [NA]
Completed clinical trial comparing a plant protein diet to an animal protein diet in individuals with Type 2 diabetes to assess effects on b…
-
CLINICAL_TRIALS withdrawal · 2015-04-30Clinical Trial Update: Regional Fatty Acid Metabolism in Humans
The Mayo Clinic-sponsored trial NCT00068887 investigating regional fatty acid metabolism in humans has been withdrawn. It concerns Type 2 di…
-
CLINICAL_TRIALS trial_result · 2015-04-28Clinical Trial Update: Diabetes Medication Choice [NA]
A Mayo Clinic–sponsored clinical trial evaluating diabetes medication choices for Type 2 diabetes has completed.
-
FDA approval · 2015-04-27FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA has approved a supplemental application for Januvia (sitagliptin) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2015-04-27FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) by Merck Sharp & Dohme LLC.
-
FDA approval · 2015-04-24FDA Approved: GLIMEPIRIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for a generic glimepiride product from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2015-04-24FDA Approved: HUMALOG MIX75/25 — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humalog Mix75/25 (insulin lispro) from Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2015-04-24Clinical Trial Update: Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients [Phase 3]
This Phase 3 trial assessed the efficacy and safety of a fixed-dose combination of linagliptin and metformin in drug-naïve adults with type …
-
CLINICAL_TRIALS trial_result · 2015-04-24Clinical Trial Update: Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin [Phase 4]
Phase 4 clinical trial update comparing pioglitazone to glimepiride in adults with type 2 diabetes inadequately controlled with metformin pl…
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin [Phase 3]
Phase 3 trial comparing a new formulation of insulin glargine with Lantus in type 2 diabetes patients on basal plus mealtime insulin; comple…
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus [Phase 3]
A Phase 3 trial compared weekly exenatide against sitagliptin and placebo to assess glycemic effects, safety, and tolerability in type 2 dia…
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy [Phase 3]
Phase 3 study comparing a new formulation of insulin glargine with Lantus in adults with Type 2 diabetes who are on non-insulin therapy; res…
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy [Phase 3]
A Phase 3 trial comparing a new formulation of insulin glargine with Lantus in type 2 diabetes patients on basal insulin and oral therapy ha…
-
FDA approval · 2015-04-22FDA Approved: PIOGLITAZONE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Pioglitazone hydrochloride, a generic thiazolidinedione used to treat type 2 diabetes mellit…
-
CLINICAL_TRIALS withdrawal · 2015-04-22Clinical Trial Update: A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin [Phase 2]
A Phase 2 placebo-controlled trial evaluating Nutralin for HbA1c change in Type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS research · 2015-04-22Clinical Trial Update: Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics [NA]
This entry summarizes a Tel Aviv University study investigating how metabolic clock gene expression in individuals with Type 2 diabetes chan…
-
CLINICAL_TRIALS research · 2015-04-21Clinical Trial Update: Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.
This clinical trial update concerns estimating glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus, including those w…